Drug Chatter -- Tracking biopharma stock chatter

💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…

Profile for Alnylam Pharmaceuticals, Inc. (ALNY)

« Back to company index

ALNY Chatter Timeline

Stock Ticker for ALNY

Most Active Tweeters for ALNY

UserTweets
@Steve_382 5
@RNAiAnalyst 4
@newsfilterio 4
@FlashAlert_me 4
@stock_titan 4

Recent Tweets for ALNY

IonisDisrupts @IonisDisrupts
@BIOTECHBATMAN @RNAiAnalyst $Alny may want to keep them on #Patisiran. That one is wholly owned and results appear similar. $sny
12:04am
RNArelics @RNArelics
RT @RNAiAnalyst: $ALNY So while primary endpoint mNIS+7 highly similar btw Vutrisiran + Patisiran (GOOD!), key secondary endpoint for Patis…
April 19th 2021, 10:04pm
RNAiAnalyst @RNAiAnalyst
$ALNY So while primary endpoint mNIS+7 highly similar btw Vutrisiran + Patisiran (GOOD!), key secondary endpoint fo… https://t.co/HJDM1CaRb5
April 19th 2021, 9:04pm
IonisDisrupts @IonisDisrupts
@RNAiAnalyst $ions adding a half point after this came out on heavy volume. $alny
April 19th 2021, 8:04pm
RNAiAnalyst @RNAiAnalyst
@Steve_382 Did $ALNY explain in webcast why they are not showing Patisiran arm? Are they afraid to harm ongoing Pat… https://t.co/i6Sf0e4tnM
April 19th 2021, 8:04pm
MarcJacksonLA @MarcJacksonLA
$ALNY Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran | Business Wire https://t.co/uQrwN379OY
April 19th 2021, 8:04pm
RNAiAnalyst @RNAiAnalyst
$ALNY congrats to positive Vutrisiran p3 data in FAP (subQ version; legacy drug Patisiran is IV)... BUT: while dat… https://t.co/f7v66UquLe
April 19th 2021, 8:04pm
Steve_382 @Steve_382
$ALNY Vutrisiran launch date early 2022. https://t.co/pukschBBwR https://t.co/UStHkZpSdi
April 19th 2021, 8:04pm
Steve_382 @Steve_382
$ALNY NDA submitted for Vutrisiran. https://t.co/mpZr8f1i7N
April 19th 2021, 8:04pm
Briefingcom @Briefingcom
$ALNY: Alnylam Pharma presents "positive" results from HELIOS-A Phase 3 study of investigational vutrisiran; to hos… https://t.co/VrnFOVbEJk
April 19th 2021, 8:04pm
glitchbotio @glitchbotio
RT @MarketCurrents: $ALNY - Alnylam submits NDA for RNAi drug vutrisiran to FDA https://t.co/51kPBiRc0x
April 19th 2021, 7:04pm
MarketCurrents @MarketCurrents
$ALNY - Alnylam submits NDA for RNAi drug vutrisiran to FDA https://t.co/51kPBiRc0x
April 19th 2021, 7:04pm
FlashAlert_me @FlashAlert_me
$ALNY [15s. delayed]: Issued Press Release on April 19, 14:00:00: Alnylam Presents Positive Results from HELIOS-A P… https://t.co/31PrtxIcDK
April 19th 2021, 6:04pm
sbwcws @sbwcws
Alnylam announces full 'positive' results from HELIOS-A Phase 3 study $ALNY
April 19th 2021, 6:04pm
newsfilterio @newsfilterio
Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran $ALNY https://t.co/c1ehkyhN9P
April 19th 2021, 6:04pm
stock_titan @stock_titan
$ALNY Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran https://t.co/QlBoQnyAmn
April 19th 2021, 6:04pm
RNAiPhD @RNAiPhD
RT @RNAiAnalyst: $ALNY catching up w/ last week...Alnylam's twice-a-year blood-lowering medication starting to have attractive efficacy pro…
April 19th 2021, 9:04am
RNAiAnalyst @RNAiAnalyst
$ALNY catching up w/ last week...Alnylam's twice-a-year blood-lowering medication starting to have attractive effic… https://t.co/59NomnkfE4
April 19th 2021, 9:04am
S20ll @S20ll
@psk2329 $ALNY ( good size position and recently added more ,but looks like was prematurely ) Thanks for taking requests
April 18th 2021, 5:04pm
newsfilterio @newsfilterio
Alnylam to Webcast Conference Call Discussing First Quarter 2021 Financial Results $ALNY https://t.co/f4Xui6LUyD
April 17th 2021, 12:04am
S20ll @S20ll
$ALNY fought 140.00 All business ?? "TDA: ALNY mark is at or above $139.99 Mark = 140.235; Impl vol = 48.96%.… https://t.co/zEVjc9HOTU
April 16th 2021, 3:04pm
equity_newswire @equity_newswire
$ALNY Alnylam to Webcast Conference Call Discussing First Quarter 2021 Financial Results https://t.co/7ntGevGkNf
April 15th 2021, 9:04pm
otcdynamics @otcdynamics
$ALNY Alnylam to Webcast Conference Call Discussing First Quarter 2021 Financial Results https://t.co/I6JOmgSpNl
April 15th 2021, 12:04pm
FlashAlert_me @FlashAlert_me
$ALNY [15s. delayed]: Issued Press Release on April 15, 08:00:00: Alnylam to Webcast Conference Call Discussing Fir… https://t.co/oBN9ODCtZQ
April 15th 2021, 12:04pm
stock_titan @stock_titan
$ALNY Alnylam to Webcast Conference Call Discussing First Quarter 2021 Financial Results https://t.co/l6f6Cen7kE
April 15th 2021, 12:04pm
Steve_382 @Steve_382
So, $XBI is up double the % of $ALNY now. Interesting
April 14th 2021, 2:04pm
Steve_382 @Steve_382
$VIR $ALNY From presentation on April 13, 2021, Vir Biotechnology, Inc. presented at the Needham & Company 20th Ann… https://t.co/EmeMcNM2h4
April 13th 2021, 9:04pm
JamesEKrause @JamesEKrause
$XBI $ALNY This marketing probe will not help biotechs. https://t.co/G4ajldIf6z
April 13th 2021, 5:04pm
XBIObserver @XBIObserver
$ALNY so is rare disease marketing now going to come under scrutiny? No wonder $XBI where it is currently. https://t.co/sDQPrnQ9Gw
April 13th 2021, 5:04pm
Steve_382 @Steve_382
$ALNY Thoughts on this 8-K? Item 8.01. Other Information. On or about April 9, 2021, Alnylam Pharmaceuticals, Inc.… https://t.co/6Nh1NC4IGm
April 13th 2021, 12:04am
MarcJacksonLA @MarcJacksonLA
$ALNY Alnylam Reports Positive Interim Results From Phase 1 Study Of ALN-AGT https://t.co/6MGl64w7pN
April 13th 2021, 12:04am
AndrewM17808654 @AndrewM17808654
@RNAiPhD I think todays SP in $ALNY suggests ongoing skepticism in RNAI programs. Consensus PTS is too low.
April 12th 2021, 11:04pm
fintel_io @fintel_io
$ALNY / Alnylam Pharmaceuticals files form 8-K - Other Events - 8-K https://t.co/7dZKSUOpGJ
April 12th 2021, 9:04pm
EdgarInsider @EdgarInsider
A Form 8-K [Press/News Current Report] filing has been made with the SEC: $ALNY #AlnylamPharmaceuticals, Inc https://t.co/rTQdVaeF4u
April 12th 2021, 9:04pm
perepujolvives @perepujolvives
RT @semodough: $ALNY – Vutrisiran NDA filing early'21; 9-mos complete results from HELIOS-A polyneuropathy at AAN (4/17-4/21)
April 12th 2021, 1:04pm
Gambiste1 @Gambiste1
RT @RNAiPhD: $ALNY Serum AGT reductions >90% sustained to 3 months w 1x ALN-AGT ?100 mg; led to >10 mm Hg reduction in 24h SBP @ 8 wks aft…
April 12th 2021, 1:04pm
Gambiste1 @Gambiste1
RT @BertrandBio: -17mmHg in 24h systolic BP vs +1mmHg PBO at wk8, sustained at w12 at 800mg, >10mmHg drop at doses> 100mg. Alnylam $ALNY…
April 12th 2021, 11:04am
DataTrials @DataTrials
$ALNY Phase 3 A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1…NCT04152200. Est… https://t.co/NhOpiHpCHQ
April 12th 2021, 11:04am
RNAiPhD @RNAiPhD
$ALNY Serum AGT reductions >90% sustained to 3 months w 1x ALN-AGT ?100 mg; led to >10 mm Hg reduction in 24h SBP… https://t.co/7FGKPQ0fbw
April 12th 2021, 9:04am
TipRanks @TipRanks
Alnylam Reports Positive Interim Results From Phase 1 Study Of ALN-AGT https://t.co/3Py75aFIWO $ALNY
April 12th 2021, 6:04am
semodough @semodough
$ALNY – Vutrisiran NDA filing early'21; 9-mos complete results from HELIOS-A polyneuropathy at AAN (4/17-4/21)
April 12th 2021, 1:04am
SteelyRivers @SteelyRivers
Alnylam RNAi candidate ALN-AGT lowers blood pressure in phase 1 trial $ALNY https://t.co/KahC4gMeI4
April 12th 2021, 1:04am
sbwcws @sbwcws
Alnylam presents late-breaking data from ongoing Phase 1 study of ALN-AGT $ALNY
April 11th 2021, 10:04pm
AndrewM17808654 @AndrewM17808654
RT @MarketCurrents: $ALNY - Alnylam RNAi candidate ALN-AGT lowers blood pressure phase 1 trial https://t.co/8BGA2BSJC3
April 11th 2021, 7:04pm
IonisDisrupts @IonisDisrupts
@MarketCurrents Treatment naive or washed out. $alny So doesn’t tell us much.
April 11th 2021, 6:04pm
newsfilterio @newsfilterio
Alnylam RNAi candidate ALN-AGT lowers blood pressure phase 1 trial $ALNY https://t.co/PWHMDzFUYc
April 11th 2021, 4:04pm
MarketCurrents @MarketCurrents
$ALNY - Alnylam RNAi candidate ALN-AGT lowers blood pressure phase 1 trial https://t.co/8BGA2BSJC3
April 11th 2021, 4:04pm
SwingTradeBot @SwingTradeBot
Recent $ALNY technical alerts: Fell Below 200 DMA plus 10 more alerts... https://t.co/fHjjjEH66J
April 11th 2021, 2:04pm
StckPro @StckPro
$ALNY NEW ARTICLE : Alnylam Presents Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT, an Investig… https://t.co/bagLoX1FfO
April 11th 2021, 2:04pm
FlashAlert_me @FlashAlert_me
$ALNY [15s. delayed]: Issued Press Release on April 11, 10:28:00: Alnylam Presents Positive Late-Breaking Data from… https://t.co/4ZSZyKweL6
April 11th 2021, 2:04pm

DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC 2004 - 2021. All rights reserved.